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Summary.-Glial fibrillary acidic protein (GFA) was assayed in nerve-tumour
extracts and located in these tumours by indirect immunofluorescence study. We
conclude that GFA is a specific marker of both malignant and normal astrocytes.
Non-astrocytic tumours (oligodendroglioma, meningioma) do not contain GFA.
Tumours with astrocytic differentiation potential (medulloblastoma) may contain
GFA. Comparison of microscopic and GFA assays leads us to conclude that GFA
concentration is proportional to the amount of malignant astrocytes in the tumour
and inversely proportional to the necrotic area of a tumour. Normal tissue GFA
and glioblastoma GFA were found to be immunologically identical.
VARIOUS unsuccessful attempts have
been made to characterize brain-tumour-
associated antigens, notably carcinoglial
antigens or foetal antigens. The character-
ization of such antigens would have
significant implications for diagnosis and
therapy of brain tumours.
We have previously reported (Delpech
et al., 1972) that heterologous immuniza-
tion of brain tumour tissue demonstrates
the absence of carcinoglial and carcino-
foetal antigen, as well as the inconstant
presence of brain glycoprotein (Warecka,
1967), a normal nervous-tissue-associated
antigen, and the quantitative decrease
of the normal nervous-system-associated
antigen NSA 2 (Delpech and Buffe, 1972;
Delpech and Delpech, 1975). The present
report deals with the quantitative and
qualitative analysis of another nervous-
system-associated antigen: the glial fibril-
lary acidic protein (GFA) (Eng et al.,
1971; Bignami and Dahl, 1973).
MATERIALS AND METHODS
Turnours. Tumour tissue was obtained at
surgery. One tumour fragment was placed in
formalin for classical histological study. A
second tumour fragment was placed in culture
medium (RPMI, Eurobio, Paris) without
serum and treated inthelaboratory within ] h
of surgery, as follows: one fragment was re-
moved from the culture medium and quickly
frozen in liquid N2 for immunofluorescence
study. Other fragments from the culture
medium were removedfor protein extraction.
The protein-extraction fragments were homo-
genized in plhosphate-buffered saline (PBS:
NaCl 8 g/l buffered to pH 7-2 with O-O1M
phosphate) with an Ultra-Turax and spun at
32,000 g for 10 min. The supernatant was
collected anddialysed against deionized water
and then freeze-dried. When assayed, the
lyophilized powder wasreintroducedinto PBS
(50 mg/ml) and the insoluble portion was
eliminated by centrifugation (12,000 g for
10 mnin). The protein content was deter-
mined by the method of Lowry et al. (1951).
GFA preparation.-GFA was partially
purified by ammonium sulphate precipitation
(Uyeda, Eng and Bignami, 1972) using sheep
and human brains obtained within 12 h of
death.
Antisera.-The nervous-system antigen
NSA 1 (Delpech et al., 1973) was verified as
being identical to GFA, through the kind
offices of Dr Bignami. We used as anti-GFA
sera the following: anti-(human foetal astro-B. DELPECH ET AL.
cyte NSA 1) serum and anti-(human glio-
blastoma NSA 1) serum (Maunoury et al.,
1976). An anti-sheep-GFA serum was pre-
pared by inoculating rabbits (1 mg/week s.c.
beginningr with the third week following the
first immunization) with sheep GFA com-
bined with Freund's complete adjuvant.
Before being used, the anti-human sera were
absorbed on to polymerized human plasma
and liver extract. The anti-sheep-GFA serum
was absorbed on to polymerized sheep plasma
and liver extract. These polymers were
prepared in a mixture of equal volumes of
plasma and liver extract (50 mg/ml) in PBS
with glutaraldehyde, according to the tech-
nique ofAvrameas and Ternynck (1969). The
antisera and polymers were incubated for
48 h (1 g polymer/ml antiserum) at room
temperature. Following incubation, the anti-
bodies were recovered by washing with PBS.
The gamma globulins were precipitated out
with 40% saturated ammonium sulphate,
reintroduced into the starting volume ofPBS
and dialyzed against a PBS volume 1000 x
the globulin volume, changing the bath once.
0'2-ml volumes were stored at -30TC.
Immunodiffusion on agarose medium (1% in
PBS) of each antiserum yielded only a single
line of precipitation when tested against its
corresponding tissue extract. This unique
line of precipitation corresponds to the GFA.
Assay of GFA.-GFA was assayed by the
radial immunodiffusion method (Mancini,
Carbonara and Heremans, 1965). Tumour
extracts were plated on agarose gel (1% in
PBS) containing 1/8 or 1/4 dilutions of anti-
sheep-GFA. After 48h diffusion and 72h
washingf in PBS, the plates were stained with
Coomassie blue (Gurr, London).
The precipitation rings were measured by
means of a micrometric optical device. 100
u/ml was arbitrarily attributed to a human
brain extract. This standard corresponds to a
value of 3 u/mg of dissolved proteins. Under
these conditions the minimum measurable
value was 0 3 u/mg.
As calculated on a sample containing the
mean dose, the standard deviation was 12%.
Immunofluorescence study. The activity of
each antiserum employed was determined on
cultured human foetal astrocytes. The follow-
ing sera were used as controls: (1) noni-
immunized rabbit serum; (2) anti-human-
liver serum or anti-sheep-liver serum; (3)
anti-GFA serum absorbed with purified
antigen (1 mg/ml).
GFA localization was determined by
standard indirect immunofluorescence. Un-
fixed and alcohol-fixed tumour slices were
studied. Anti-GFA sera in 1/20 and 1/50
dilutions were left in contact with each slice
for 30min at laboratory temperature. The
fluorescence-labelled anti-rabbit globulin (In-
stitut Pasteur, Paris) was used at a dilution of
1/20. The reactions were considered to be
specific for GFA when they occurred uniquely
with the anti-GFA serum. In order to
distinguish normal tissue from tumorous
tissue, we studied by classical histological
methods the serial microscopic sections
immediately following each slice that was
studied immunologically.
RESULTS
These are reported in the tables.
Astrocytomas
No immunochemical difference was
found to exist between tumour GFA and
normal human or sheep GFA, as evaluated
by the immuinodiffusion technique. Simi-
larly, the anti-GFA activity of our anti-
glioblastoma serum was consistently abol-
ished by normal human or sheep GFA.
This identical character of the antigens
was further confirmed by immunohisto-
chemical study. We have therefore con-
cluded that there is no tumour-specific
antigenic structure of GFA (Table I).
GFA activity was found in the 14 astro-
cytomas studied. The mean activity was
4*5 u/mg. In 4 cases the value was <2
u/mg, in 8 cases 2-7 u/mg, and in 2 cases
>7 u/mg. The extreme values were 0 4
u/mg and 19-8 u/mg. No striking differ-
ence was found between the Grade III
astrocytomas (5 cases, mean-4-4) and
the Grade IV astrocytomas (8 cases, mean
_5.3). The means are greater than those
found for either human or sheep whole-
brain extracts (Table II). The highest
values (Cases No. 6 and 11 in Table II)
correspond to those tumours which con-
tained little necrotic material and much
cellular tissue. At the other extreme, the
lowest value (Case No. 7) corresponded to
a polymorphous tumour which, in addition
toacharacteristic Type-IVzone, contained
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TABLE I.-Absence of Tumour-specific Antigen is Demonstrated by Cross Absorption of
Anti-glioblastoma Serum by Sheep GFA and Human GFA. The Anti-GFA Reactivity was
Studied by Immunoprecipitation and Immunoftuorescence (*Immunoprecipitation Only)
Reactivity with
Antiserum
Anti-foetal-astrocytes
Anti-glioblastoma
Anti-sheep-GFA
Absorbed with
Plasma+liver
Sheep GFA
Human GFA
Plasma+liver
Sheep GFA
Human GFA
Plasma+liver
Sheep GFA
Human GFA
Human brain Sheep brain* Glioblastomas
+
+
+
±
+
+
+
+
+
TABLE II.-GFA Content in Brain Tissue Extracts, Including Glioma Extracts and
Medulloblastoma Extracts. f Fibrillary; c=Cellular; pv=Perivascular; w weak;
na=Normal Astrocytes; n=Necrosis; ND=Not done
Tissues
Adult human brain
Newborn human brain
Sheep brain
A8trocytomas
1. Fon.
2. Ler.
3. Has.
4. Dai.
5. Sai.
6. Nev.
7. Rou.
8. And.
9. Fre.
10. Imb.
11. Lan.
12. Per.
13. Lav.
14. Mou.
Immunofluorescence
Units/nig (location)
3 +(na; f; c)
0 3 ND
3 ND
Grade
II
III
III
III
III
III
IV
IV
IV
IV
IV
IV
IV
IV
Cell den8ity
++
++
++
++
++
polymorph
++
±+
+++
+
Oligodendrogliomas
15. Col.
16. Lep.
17. Nic.
Medulloblastomas
18. Mar.
19. Lec.
differentiation tissue of the ependymoma
and oligodendroglioma varieties. The
other cases of low activity (Nos. 5, 9 and
12) correspond to highly necrotic tumours.
Immunofluorescence study of the 3 anti-
sera, anti-glioblastoma, anti-foetal-astro-
cytes and anti-sheep-GFA, did not reveal
any difference between them. The im-
munofluorescence study yielded 2 types of
immunofluorescent pattern: (i) in all the
cases we observed immunofluorescence
3-3
4-2-3-9
3-1
3 -5
1 *8 9.7
1 4-04
3-8
1 *6
4-8
19-8
1-3
6-6
3 *6-3
2*2-0-2
ND
ND
1 6-4-2
ND
+(f; c)
ND
0 (n)
-+ (f)
+ (f;w)
+ (f; c)
+ (f; pv)
ND
ND
+ (f; c)
ND
+ (f)
+ (f;pv)
+ (f)
0 (+, na)
0
0
0
staining of filaments of the malignant cell
(Fig. lb); in some cases this was associated
with perivascular staining (Fig. 1c); (ii) in
two cases we observed immunofluorescence
labelling at the periphery of malignant
astrocytic cell bodies (Fig. 2). Specific
labelling was not observed in the necrotic
areas. The intensity and brilliance of the
immunofluorescent filamentous staining
varied in different tumours, and were seen
to be proportional to each tumour's GFA
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content. Significant cytoplasmic staining
was observed only in healthy astrocytes
which sometimes contaminated the tum-
our samples.
Contaminating normal astrocytes were
distinguished from malignant astrocytes
by classical histological study of the
immediately successive microscopic sec-
tion. The irregular aspect of tumour-cell
nuclei was also identified in the immuno-
histological studv.
Other intracranial tumours
Two medulloblastomas were studied. In
one medulloblastoma we were able to
detect specific labelling that was confined
to some malignant cells (Fig. 3). Three
oligodendrogliomas were studied, ofwhich
FIG. 1(a).-Glioblastoma No. 13: classical staining method (x 13 objective).
IG. l(b).-Glioblastoma No. 13: GFA in the dense fibre network (x 40 objective).
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FIG. I(c).-Glioblastoma No. 13: the vascular lumen takes up almost the entire photograph. In the
lower left hand corner notice the perivascular GFA condensation ( x 40 objective).
~~~~~~. *fr~~~~~~~~~~~~~~~~~~4i 4 IL
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FIG. 2(a).-Astrocytoma No. 6: classical stainngmethod (x 13 objective).
one was positive for GFA. However,
immunohistological study clearly demon-
strated that only normal cells had been
labelled, excluding any labelling of malig-
nant cells. Similarly, only normal cells
were labelled in the cerebral reticulosar-
comathat we studied.
on-nerroQw extracranial tumours
NXone of these contained sufficient GFA
to be detected bv our methods.
DISCUSSION
Our results confirm that GFA is an
essential constituent of astrocytes, and
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FIG. 2(b).-Astrocytoma No. 6: both the cell bodies and the fibres are immunologically stained. In
many malignant cells the huge nucleus pushes the cytoplasm to the cellular periphery where it is
no more than a thin layer ( x 40 objective).
FIG. 3.-GFA in Medulloblastoma No. 18. In this section only a few cells containGFA ( x 13objective).
demonstrate that inastrocvtomasthe GFA
seems to be essentially located in the cell
fibres. Furthermore our results suggest
that concentration of GFA in the tumour
extract is dependent upon 3 factors:
(1) the relative proportion of malignant
astrocytes; (2) the extent ofnecrosis; and
(3) contamination of tumour by healthy
tissue. Factor 1 seems to have the effect of
increasing the GFA content. Factor 2
lowers the GFA content.
The differences in our measured GFA
values can be accounted for by the effects
of these 3 factors. For example in Case
38GFA IN TUMOURS OF NERVOUS SYSTEM
TABLE III.-GFA Content in Intracranial Tumours Other than
Gliomas, and in Extracranial Tumours
Tissues
Meningiomaw
20. Leg.
21. Ler.
22. Aug.
23. Glo.
24. Oli
25. Dam.
Reticulosarcoma
26. Pet.
Melanoma brain metastasis
27. Deb.
Sympathoblastoma
28. Cha.
Fibrosarcomas
29. Gri.
30. Hua.
31. Rou.
Hepatomas
32. Rou.
33. Mic.
Gastric carcinoma
34. Han.
Breast carcinoma
35. Sim.
Chordoma
36. Bro.
Melanomas
37. Des.
38. Dum.
No. 7 two different fragments of the same
tumour yielded significantly different GFA
values. This example is particularly in-
formative, because microscopic study indi-
cated that this tumour was a polymorph-
ous tumour which demonstrated GFA
activity only in those areas which corres-
ponded to astrocytic differentiation. Such
polymorphism is not a rarity in astrocyto-
mas. Consequently, quantification cannot
be very significant unless itis accompanied
by histological study of the astrocytomas.
Cases No. 6 and 11 confirm the relation
between the tumour's malignant astrocyte
density and its GFA content. In addition
our results demonstrate that the GFA
assay values can be affected by the pres-
ence of non-tumour tissue that is some-
times macroscopically indistinguishable
from actual tumour tissue, especially in
the casesofoedematous, otherwisehealthy,
nervous tissue and infiltrating tumours.
Units/mg
1*6
0
0
0
0
0
3 -4
0
0
0
0
0
0
0
0
0
0
0
0
Immunofluorescence
0 (+, na)
0
0
0
0
0
0 (+, na)
0
0
ND
0
ND
ND
ND
0
0
ND
0
0
Therefore, taking into account the 3
factors mentioned above, our results are
consistent. Also our quantitative results
are in agreement with the recently pub-
lished results of Dittmann et al. (1977),
which showed that the GFA concentration
in astrocytomas is 1 2-6 times the GFA
concentration found in normal brain
tissue.
The negative findings in the study of
non-astrocytic tumours are consistent
with the finding that GFA is restricted to
the astrocyte.
Although in the case of one medullo-
blastoma GFA was found to be present, its
presence does not invalidate our interpre-
tation. It is well known that in the midst
ofa medulloblastoma many different types
of cellular differentiation may be en-
countered. Therefore, it appears that the
very presence of GFA in a tumour is
indicative of the presence of astrocytic
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differentiation. We feel that the study ofa
greater number of tumours would confirm
this opinion.
We are greatly obliged to Dr Bignami (Boston,
Mass.) who kindly analysed our antiserum and
provided us with a sample of his anti-GFA.
This work was subsidized by the Universite de
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